Phase 1b clinical trials in Ghent Ongoing

Written By Matt Ang

The INDIGO project and its partners are thrilled to announce the commencement of a Phase 1b clinical trial for a novel, adjuvant influenza vaccine specifically targeting the older population. This trial is a significant step forward in our collaborative efforts within the INDIGO project to enhance seasonal influenza vaccines and develop new solutions for pandemic influenza.

The implementation of Phase 1b clinical trials began in Ophemert/Ghent, Netherlands/Belgium last March 2024. This trial is in collaboration with the Center for Vaccinology (Ghent), Harmony Clinical Research (Melle), and LiteVax BV (Ophemert). Our main objectives for this trial are to evaluate safety, immunogenicity, and immunological mechanisms related to this vaccine.

You can read LiteVax's press release about the clinical trials here: https://lnkd.in/enXFdpKY

Matt Ang
Previous

Breakthrough in Flu Vaccine Research: indigo’s Adjuvant Shows Promise in Humans
Next

Jantine van Wijlick presents oral abstract at the European congress on Global Health (ECTMIH2023)